HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAM JAPAN HDG

28.380

-0.120-0.42%

Volume:91.40K

Turnover:2.61M

Market Cap:1.82B

PE:- -

High:28.760

Open:28.460

Low:28.360

Close:28.500

52wk High:31.020

52wk Low:16.923

Shares:64.20M

HK Float Shares:21.50M

Volume Ratio:1.03

T/O Rate:0.43%

Dividend:0.33

Dividend Rate:1.16%

ROE:--

ROA:--

PB:--

PE(LYR):- -

PS:- -

Loading ...

Overview Company News Filings

Elliott Builds Stake in Japan Shipping Giant Mitsui O.S.K. Lines -- Update

Market Chatter: BYD Japan Says Carmaker Can't Compete Domestically as EV Subsidy Revision Favors Others

MT Newswires Live

Market Chatter: Nissan, Toyota Trim Production Amid Middle East Supply Shock

MT Newswires Live

Press Release: Fold Holdings, Inc. (NASDAQ: FLD) Announces Fourth Quarter and Full Year 2025 Results

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

After I totaled my car, I set out to find a used one for under $10,000

Namibia Critical Metals Adds Toyota Tsusho as Strategic Partner at Lofdal Rare Earths Project

MrBeast's finance app for kids is backed by a bank that's faced regulatory scrutiny and a fintech partner's failure

Press Release: Sofwave Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Achieves Full-Year Profitability

Press Release: Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth

Press Release: Abeona Therapeutics(R) Reports Full Year 2025 Financial Results and Corporate Updates

Press Release: AEye Reports Fourth Quarter and Full-Year 2025 Results; Strengthened Foundation for Commercial Growth

Press Release: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Press Release: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Opening Day: SoftBank payments app operator makes public debut

Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Press Release: Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Press Release: BALYO Announces Its 2025 Results, Marked by a Further Increase in Revenue (+8%) to EUR31.4 Million

Toyota Hit By Major US Recall Of 550,000 SUVs

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/03160/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"03160","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03160\",,,,,undefined,":{"symbol":"03160","market":"HK","secType":"STK","nameCN":"CAM JAPAN HDG","latestPrice":28.38,"timestamp":1774598186216,"preClose":28.5,"halted":0,"volume":91400,"delay":0,"changeRate":-0.004210526315789508,"floatShares":21500000,"shares":64200000,"eps":0,"marketStatus":"Market Closed","change":-0.12,"latestTime":"03-27 15:56:26","open":28.46,"high":28.76,"low":28.36,"amount":2606132,"amplitude":0.014035,"askPrice":28.5,"askSize":1000,"bidPrice":28.3,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":7,"adr":0,"listingDate":1455724800000,"exchange":"SEHK","adjPreClose":28.5,"sharesOutstanding":32400000,"nav":28.5816,"aum":690018436.003,"dividendRate":0.011628,"bidAskSpread":0,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":1.0301609487917949,"lotSize":200,"spreadScale":3,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03160\",,,,,undefined,":{"symbol":"03160","floatShares":21500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0301609487917949,"shares":64200000,"dividePrice":0.33,"high":28.76,"amplitude":0.014035,"preClose":28.5,"low":28.36,"week52Low":16.923,"pbRate":"--","week52High":31.02,"institutionHeld":0,"latestPrice":28.38,"committee":-0.666667,"eps":0,"divideRate":0.011628,"volume":91400,"delay":0,"ttmEps":0,"open":28.46,"prevYearClose":26.6,"prevWeekClose":28.42,"prevMonthClose":31,"prevQuarterClose":26.6,"fiveDayClose":28.42,"twentyDayClose":31,"sixtyDayClose":26.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03160\",params:#limit:5,,,undefined,":[{"date":"2026-04-01","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-04-02","defaultRemindTime":1775007000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-10","payableDate":"2026-04-02","currency":"HKD","dateTimestamp":1774972800000,"payDate":"2026-04-10"},{"date":"2025-10-02","symbol":"03160","amount":0.18,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-10-03","defaultRemindTime":1759368600000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-10","payableDate":"2025-10-03","currency":"HKD","dateTimestamp":1759334400000,"payDate":"2025-10-10"},{"date":"2025-04-01","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-04-02","defaultRemindTime":1743471000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-08","payableDate":"2025-04-02","currency":"HKD","dateTimestamp":1743436800000,"payDate":"2025-04-08"},{"date":"2024-10-03","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2024-10-04","defaultRemindTime":1727919000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-10","payableDate":"2024-10-04","currency":"HKD","dateTimestamp":1727884800000,"payDate":"2024-10-10"},{"date":"2024-04-03","symbol":"03160","amount":0.12,"announcedDate":null,"type":"dividend","market":"HK","newRecordDate":"2024-04-05","defaultRemindTime":1712107800000,"name":"华夏日股对冲","recordDate":"2024-04-12","payableDate":"2024-04-05","currency":"HKD","dateTimestamp":1712073600000,"payDate":"2024-04-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03160\",market:\"HK\",,,undefined,":[{"executeDate":"2017-03-30","recordDate":"2017-03-31","paymentDate":"2017-04-07","value":0.08,"currency":"HKD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-06","value":0.04,"currency":"HKD"},{"executeDate":"2018-03-28","recordDate":"2018-03-29","paymentDate":"2018-04-09","value":0.08,"currency":"HKD"},{"executeDate":"2018-10-02","recordDate":"2018-10-03","paymentDate":"2018-10-09","value":0.09,"currency":"HKD"},{"executeDate":"2019-04-01","recordDate":"2019-04-02","paymentDate":"2019-04-09","value":0.07,"currency":"HKD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03160\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03160\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620284168","title":"Elliott Builds Stake in Japan Shipping Giant Mitsui O.S.K. Lines -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620284168","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620284168?lang=en_us&edition=fundamental","pubTime":"2026-03-18 14:00","pubTimestamp":1773813600,"startTime":"0","endTime":"0","summary":"Elliott Investment Management has built a stake in Mitsui O.S.K. Lines, saying the Japanese shipping giant is materially undervalued despite its business strength, the latest in a series of activist moves targeting prominent Japanese companies.The U.S. activist investor said late Tuesday that its significant investment reflected its belief in the Japanese company's strength in shipping and its standing as a major owner of oceangoing vessels.Elliott said Mitsui O.S.K.'s stock is materially undervalued despite its business strength and high-quality assets.The activist investor said it sees an opportunity to work constructively with the shipping company to ensure its medium-term management plan is appropriately ambitious, and to deliver the premium valuation it deserves.Mitsui O.S.K. handles a variety of cargoes, including grain, metals, energy and cars, and is also engaged in the real-estate business. The company took its key real-estate subsidiary Daibiru private in 2022.A spokesman for","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4604","BK4099","BK4555","03160","TM"],"gpt_icon":0},{"id":"2620813284","title":"Market Chatter: BYD Japan Says Carmaker Can't Compete Domestically as EV Subsidy Revision Favors Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2620813284","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620813284?lang=en_us&edition=fundamental","pubTime":"2026-03-18 13:51","pubTimestamp":1773813105,"startTime":"0","endTime":"0","summary":"The head of BYD's  Japan unit said the carmaker could not compete domestically after the government revised the subsidies on electric vehicle purchases for a range of automakers, Nikkei Asia reported Tuesday.None of BYD's four models in Japan were granted a subsidy increase, while those from Toyota Motor , Tesla and others saw substantial rises.\"The gap [with companies like Toyota Motor] has grown to up to nearly 1 million yen. We can't compete with 350,000 yen,\" Atsuki Tofukuji, the head of BYD's Japan unit, reportedly said.According to the report, the maximum subsidy for EVs was revised upwards by 400,000 yen to 1.3 million yen, though those for BYD remained in the 350,000 yen to 450,000 yen range.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BYDDY","LU1303224171.USD","LU0164865239.USD","LU1997244956.HKD","LU0516422440.USD","LU0543330566.HKD","LU2097828557.USD","LU0417516902.SGD","LU0516423091.SGD","LU0708995583.HKD","LU1328277881.USD","LU0531970944.HKD","BK0014","LU2328871848.SGD","LU0229945570.USD","LU1820825898.SGD","LU2449936058.SGD","LU0084288322.USD","BK0183","BK1610","LU0449515922.USD","LU2580892789.USD","BK4099","LU0979878070.USD","LU0634319403.HKD","LU1188198961.HKD","81211","LU0164872284.USD","LU1242518857.USD","LU0359202008.SGD","HYDD.SI","BK1119","LU1997245094.SGD","LU0175139822.USD","LU0823414478.USD","LU1794554557.SGD","LU2506951792.HKD","LU1720050803.USD","BK1509","LU0828238088.HKD","LU1146622755.USD","LU1880383366.USD","SG9999014674.SGD","LU0823426308.USD","LU0165289439.USD","LU0594300179.USD","LU0449509016.USD","LU0856984785.SGD","SG9999001226.SGD","LU1064131003.USD","LU0244354667.USD","LU0823039010.USD","BK0072","BK4555","SG9999002463.SGD","LU1808992512.USD","LU0417516738.SGD","LU1781817850.SGD","BK1522","LU0289961442.SGD","LU0588546209.SGD","LU1719994722.HKD","LU2495084118.USD","SG9999006514.SGD","LU0823038988.USD","LU0348827113.USD","LU0314109678.HKD","BK1582","LU0593848301.USD","IE00BD6J9T35.USD","LU0531971595.HKD","BK0196","LU0865486749.SGD","01211","LU0254981946.USD","LU0211977185.USD","LU2357125470.USD","LU2148510915.USD","LU2097828714.EUR","LU0320764599.SGD","SG9999015945.SGD","LU0054450605.USD","LU2476274720.SGD","LU0540923850.HKD","002594","LU0633140560.USD","LU1868837565.USD","BK0169","LU2097828631.EUR","BK0188","LU1868837722.USD","LU1868838027.USD","SG9999002828.SGD","LU1242518931.SGD","LU0650527681.SGD","BK1540","LU0043850808.USD","BK1539","LU0871576103.HKD","LU0463099449.HKD","LU0823426480.USD","03160","LU2399975544.HKD","LU0572944931.SGD","LU0511384066.AUD","LU0469268626.HKD","TM","LU2097828474.EUR","LU1813983027.USD","LU0348805143.USD","LU0594300419.USD","LU0588545730.USD","BK4585","LU1997245177.USD","LU0505663152.USD","BK4604","LU1580142542.USD","LU1861219969.SGD","LU2476274308.USD","LU2348774022.SGD","LU2289578879.USD","LU0039217434.USD","LU0823414551.USD","LU1508157978.USD","LU1251922891.USD","BK4588","LU1969619763.USD","LU2663582299.SGD","SG9999015952.SGD","LU0561508036.HKD","LU0683595622.HKD","LU2153592121.USD","LU0052750758.USD","LU0214875030.USD","SG9999015986.USD","LU0633140727.USD","LU0143863198.USD","LU2249611893.SGD","LU1961090484.USD","LU0289960550.SGD","LU2580892862.HKD","LU0605514214.HKD","BK0155","LU0259732245.USD","LU1880383440.USD","LU2039709279.SGD","LU1861214812.USD","LU0289739343.SGD","SG9999015978.USD","LU0269904917.USD","LU0326950275.SGD","LU0588545490.SGD","BK0264","LU0516422952.EUR","BK0070","LU0516422366.SGD","LU1023057109.AUD","EVS.SI","LU0819121731.USD","LU0307460666.USD","LU0819123356.HKD","LU2097828805.USD","LU2360107325.USD","LU0143863784.USD","LU2778985437.USD","LU0348735423.USD","LU0348825331.USD","LU0516423174.USD","BK1594","LU0327786744.USD","LU0359201612.USD","SG9999006597.SGD","LU0359201885.HKD","LU0315178854.USD","LU1770034418.SGD","LU2294711713.HKD","LU0509642566.USD","LU1064130708.USD","LU0588545904.SGD"],"gpt_icon":1},{"id":"2620028154","title":"Market Chatter: Nissan, Toyota Trim Production Amid Middle East Supply Shock","url":"https://stock-news.laohu8.com/highlight/detail?id=2620028154","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620028154?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:26","pubTimestamp":1773793590,"startTime":"0","endTime":"0","summary":"Nissan Motor  and Toyota Motor  are cutting production as disruption in the Strait of Hormuz halts shipments to the Middle East, Nikkei reported Wednesday.Nissan will reduce output by about 1,200 vehicles this month at its Kyushu unit, adjusting production as exports to the region stall, while maintaining output of key models such as the Patrol, according to the report.Toyota plans to cut about 20,000 Middle East-bound vehicles by end-March, with total reductions seen reaching around 40,000 units by end-April, the report said.The Middle East remains a core market, accounting for roughly 30% of regional auto sales for Japanese brands, but shipping suspensions have left car carriers stranded and exports delayed, according to the report.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4099","TM","BK4588","BK4555","BK4585","03160","BK4604"],"gpt_icon":0},{"id":"2620640847","title":"Press Release: Fold Holdings, Inc. (NASDAQ: FLD) Announces Fourth Quarter and Full Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620640847","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620640847?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:15","pubTimestamp":1773778500,"startTime":"0","endTime":"0","summary":"2025 Transaction Volumes of $960 million, 46% YoY increase. Launch of Fold Bitcoin Credit Card and Enterprise Services. PHOENIX, March 17, 2026  -- Fold Holdings, Inc.  , the first publicly traded bitcoin financial services company, today announced financial results for the fourth quarter and full year ended December 31, 2025.-- Total Verified Accounts: 84,000, +13,000 new in the year. -- Total Transaction Volume: $215 million; 3% YoY decrease. \"We closed our first full year as a public company with strong execution against the goals we set coming into 2025,\" said Fold Chairman and CEO Will Reeves. \"In the fourth quarter, revenue was $9.1 million, up 8.2% year-over-year, and for full year 2025 revenue was $31.8 million, up 34% year-over-year. We continued to add customers and expand our platform while building the foundation to scale a Bitcoin-native financial services ecosystem across multiple interconnected product lines.\". \"Our second major product milestone this quarter was the lau","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JEPQ","BITI","PSQ","ARKB","BK1611","QLD","BK4594","QQQE","03160","TQQQ","SBIT","QYLG","USJW.SI","FLD","QQQY","BTCO","TSYW.SI","GPIQ","83042","USAW.SI","BK4555","BK4585","MNQmain","BTC","QID","BITB","BK4604","FBTC","QQQJ","BK4112","BITO","NQmain","MBTmain","BK4601","GBTC","BITU","SQQQ","BK4099","NVIW.SI","BK4588"],"gpt_icon":1},{"id":"2620682408","title":"Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620682408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620682408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:05","pubTimestamp":1773777900,"startTime":"0","endTime":"0","summary":"Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough. On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026. Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028. Management to host a conference call and webcast today at 4:30 p.m. ET. NEW HAVEN, Conn., March 17, 2026  -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis , non-IPF interstitial lung disease , and refractory chronic cough , today announced financial results for the fourth quarter and year ended December 31, 2025, and provided business updates.overall alignment on the plan for the remai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","TRVI","BK4585","LENZ","BK4588","TM","LABU","BK4604","BK4555","RCC","BK4007","BK4539","BK4099","BK4139"],"gpt_icon":0},{"id":"2620951478","title":"After I totaled my car, I set out to find a used one for under $10,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2620951478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620951478?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:51","pubTimestamp":1773755460,"startTime":"0","endTime":"0","summary":"The average used car now costs around $26,000. Here's how I bought a Lexus for $8,000.In this week's Don't Short Yourself, here's how I bought this used Lexus for just $8,000.Welcome back to Don't Short Yourself, where each week we offer practical money moves to help you make smarter decisions with your hard-earned cash.After totaling my 2010 Toyota RAV4 at the end of 2024, I set out to find a used set of reliable wheels for under $10,000, without financing it.First, I narrowed my search to familiar older-model cars. On the advice of a friend, I started exploring luxury brands associated with Toyota  and Honda , namely Lexus and Acura. My family drove Toyota and Honda cars when I was growing up, so I already knew how long those vehicles can last when they're well-maintained.I then learned how to read a Carfax vehicle-history report to check for past maintenance problems. That kind of homework matters, says Joseph Yoon, a consumer-insights analyst at Edmunds. He says used cars under $10","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMC","BK4604","BK4099","BK4588","BK4555","BK4585","TM","MZDAY","03160"],"gpt_icon":0},{"id":"2620420511","title":"Namibia Critical Metals Adds Toyota Tsusho as Strategic Partner at Lofdal Rare Earths Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420511","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420511?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:18","pubTimestamp":1773753525,"startTime":"0","endTime":"0","summary":"Namibia Critical Metals Inc ( ($TSE:NMI) ) has issued an announcement. Namibia Critical Metals Inc. has brought in Toyota Tsusho Corporation as a s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/namibia-critical-metals-adds-toyota-tsusho-as-strategic-partner-at-lofdal-rare-earths-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/namibia-critical-metals-adds-toyota-tsusho-as-strategic-partner-at-lofdal-rare-earths-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4099","03160","TM","BK4585","BK4555","BK4604","BK4588"],"gpt_icon":0},{"id":"2620042733","title":"MrBeast's finance app for kids is backed by a bank that's faced regulatory scrutiny and a fintech partner's failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2620042733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620042733?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:58","pubTimestamp":1773752280,"startTime":"0","endTime":"0","summary":"The YouTuber's new fintech venture relies on Evolve Bank & Trust, a partner bank of the now-collapsed Synapse that has dealt with numerous setbacks.MrBeast, who acquired teen banking app Step in February, has built a business empire on top of his 470 million YouTube subscribers - but his latest financial venture is drawing scrutiny over its reliance on Evolve Bank & Trust.On a chilly October morning last year in Memphis, Tenn., a federal agent watched as a dark-colored Mazda SUV pulled into the parking lot of Evolve Bank & Trust. The driver was Robert Hartheimer, the recently appointed chief executive of the Memphis-based bank.Now, the biggest YouTuber in the world has tied his name to Evolve Bank. Jimmy Donaldson, better known as MrBeast, acquired Step Financial in February. Step describes itself as a banking app for teens and young adults starting their financial journeys, but it's not a government-chartered bank. It depends on Evolve to provide the regulated banking services behind ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","LU0390134368.USD","CONI","LU2720916845.USD","LU0689626769.HKD","LU0354030438.USD","LU0056508442.USD","BK4539","LU0289961442.SGD","LU0345774631.USD","LU1116320901.HKD","LU1935043536.SGD","LU0127658192.USD","LU0289739343.SGD","LU0472753341.HKD","LU0256863902.USD","LU2087625088.SGD","LU0310800379.SGD","COIA","LU1935042215.USD","LU0823417737.USD","LU0353189680.USD","LU0965509101.SGD","LU0128525929.USD","LU1043141396.HKD","LU0511384066.AUD","LU1670756490.USD","LU1670627923.USD","LU1791710582.SGD","LU2361044949.HKD","LU1934455863.HKD","LU1814569148.SGD","COYY","LU0109392836.USD","LU1267930573.SGD","LU2023250843.SGD","LU0476273544.USD","LU0942090050.USD","LU1228905540.USD","LU1803068979.SGD","LU0823421416.USD","LU1043141123.HKD","LU1861559042.SGD","LU0690374961.EUR","BK4588","LU1852331112.SGD","LU2764262908.HKD","LU2506951958.HKD","SG9999014906.USD","LU2023251221.USD","IE00BWXC8680.SGD","LU2360107671.USD","SGXZ99366536.SGD","LU0234572021.USD","LU0354030511.USD","LU2244417387.USD","LU1935042488.USD","LU0708994859.HKD","LU2125154935.USD","LU2361044865.SGD","LU1236620750.USD","LU2471134879.HKD","LU0994945656.USD","LU1035775433.USD","LU1429558221.USD","BK4598","LU2506952097.USD","SG9999000418.SGD","BK4112","LU0342679015.USD","LU0708995401.HKD","LU0823421333.USD","BK4535","SG9999001424.SGD","BK4534","LU2125154778.USD","LU1267930730.SGD","LU2111349929.HKD","LU2471134952.CNY","LU0234570918.USD","LU1400636657.SGD","SG9999017495.SGD","BK4527","LU1917777945.USD","LU2361045086.USD","LU0215105999.USD","LU1280957306.USD","BK4227","LU2764263203.CNY","LU0124676726.USD","LU0175139822.USD","LU1989772923.USD","LU0965508806.USD","LU0251132253.USD","LU0417517546.SGD","03160","LU1064131342.USD","LU1934455194.USD","LU2764263039.SGD","V","LU1069344957.HKD","SG9999014914.USD","LU2746668974.SGD","IE00B1BXHZ80.USD","IE00B19Z8W00.USD","AFRU","LU0079474960.USD","LU0097036916.USD","GB00B4LPDJ14.GBP","SGXZ31699556.SGD","SFTBY","LU0965509010.AUD","LU2028103732.USD","LU2461242641.AUD","BK4585","AFRM","LU0345774391.USD","LU1691799644.USD","LU2404859667.USD","LU0957808578.USD","IE00BQXX3D17.EUR","LU1988902786.USD","LU1046421795.USD","LU2237438978.USD","BK4551","BK4596","LU1712237335.SGD","LU1935042991.SGD","BK4554","LU1804176565.USD","LU0557290698.USD","LU1202635105.USD","LU1363072403.SGD","LU2264538146.SGD","LU0256863811.USD","LU2750360997.AUD","LU2242649171.HKD","IE00BZ1G4Q59.USD","LU2471134523.USD","LU0048584097.USD","LU0187121727.USD","LU2265009873.SGD","IE00B1XK9C88.USD","LU0225283273.USD","LU1116320737.USD","IE00BKDWB100.SGD","FIAT","LU1989772840.SGD","BK4548","SG9999018865.SGD","LU0006306889.USD","LU0861579265.USD","LU2106854487.HKD","BK4533","IE00BQXX3F31.USD","SG9999018857.SGD","LU0265550946.USD","LU1366333091.USD","LU1935043023.USD","LU0289941410.SGD","CONX","LU2326559502.SGD","LU2506952170.USD","LU0642271901.SGD","LU1645745479.HKD","LU2097829019.USD","LU2404859741.USD","LU2089283258.USD","LU1623119135.USD","LU0690374615.EUR","LU1435385759.SGD","LU1400636574.HKD","LU2506951875.HKD","BK4106","LU0950375773.USD","LU1815333072.USD","LU1037948541.HKD","LU2023250504.SGD","SGXZ81514606.USD","LU0057025933.USD","LU0109391861.USD","LU0868494617.USD","BK4559","ICOI","LU0444973449.USD","LU0096362180.USD","LU0683600562.USD","LU1121112475.USD","LU0444971666.USD","COII","LU0348723411.USD","LU0957791311.USD","LU2746668461.USD","LU1815336760.USD","LU1236620834.HKD","LU0289960550.SGD","BK4581","LU0353189763.USD","LU0316494557.USD","LU1037948897.HKD","LU2271345857.HKD","IE00BQXX3C00.GBP","GB00B4QBRK32.GBP","LU0426412945.USD","LU0106261372.USD","LU0672654240.SGD","LU0889565833.HKD","LU1861220207.SGD","LU1791710400.SGD","LU2089284900.SGD","SGXZ51526630.SGD","LU0061474960.USD","LU0157215616.USD","LU0265550359.USD","COIO","LU0158827781.USD","LU1934455277.USD","LU1642822529.SGD","COIG","IE00B19Z9505.USD","IE00BKVL7J92.USD","LU0528227936.USD","BK4595","LU0426417589.USD","LU0545562505.USD","LU0787776722.HKD","BK4516","BK4600","LU0640476718.USD","LU0823417653.USD","LU0823434740.USD","SG9999014898.SGD","LU0965509283.SGD","LU1228905037.USD","LU1861558580.USD","BK4132","LU1400636491.USD","LU0320765059.SGD","LU0170899867.USD","SG9999014880.SGD","LU0868494708.USD","LU0158827948.USD","LU2471134796.USD","IE00B19Z8X17.USD","LU0029864427.USD","LU0971096721.USD","LU1823568750.SGD","LU2750360641.GBP","LU1633808545.USD","LU0069063385.USD","LU1861217088.USD","COIW","LU1974910355.USD","LU2360032135.SGD","CONY","LU1670628061.USD","LU1316542783.SGD","LU0823434583.USD"],"gpt_icon":1},{"id":"2620422883","title":"Press Release: Sofwave Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Achieves Full-Year Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422883","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422883?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":"-- Record quarterly revenue in fourth quarter of $28.9M, +58% year-over-year. -- Fourth quarter pulse recurring revenue of $13.2M, +83% year-over-year. -- Full fiscal year 2025 revenue of $87.6M, +47% year-over-year growth; IFRS. -- Company achieves net profitability with full fiscal year 2025 IFRS and. non-IFRS net income of $5.5M and $7.8M, respectively, versus a net loss. of $4.5M and $2.1M, respectively, in the same period last year. -- Approximately 2,700 Sofwave systems sold to date and more than 770,000. -- Installed base continues to expand globally with systems placed across. Fourth Quarter and Full Fiscal 2025 Financial Highlights. -- Fourth Quarter Revenue of $28.9M; representing 58% year-over-year growth. -- Gross Profit was $21.9M, a year-over-year increase of 55%. \"Sofwave closed 2025 on a high note, delivering fourth quarter revenue of approximately $28.9 million -- a 58% year-over-year increase -- and generated full-year revenue of approximately $87.6 million, represent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Sofwave Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Achieves Full-Year Profitability","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4604","03160","BK4555","BK4585","BK4099","TM"],"gpt_icon":0},{"id":"2620240434","title":"Press Release: Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2620240434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620240434?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":"PITTSBURGH, March 17, 2026  -- Longevity Health Holdings, Inc.   announced that its Board of Directors has appointed Ram Ajjarapu as Chairman and Chief Executive Officer, effective as of March 16, 2026.\"Ram brings a strong track record of scaling businesses and executing value-creating transactions,\" said Rajiv Shukla, outgoing Chairman and Chief Executive Officer. \"We look forward to his leadership as Longevity seeks to advance its growth strategy through acquisitions as a public company.\". \"I am excited to join Longevity and help build the Company's acquisition platform,\" said Mr. Ajjarapu. \"My investment and leadership commitment reflect my confidence in Longevity's potential. We intend to pursue disciplined, value-accretive acquisitions that expand our operations, are accretive to earnings, grow profitability, and create long-term value for our stockholders while maintaining a prudent capital structure.\". Longevity is a bio-aesthetics company focused on longevity and healthy aging.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4139","BK4099","BK4555","BK4585","BK4588","TM","XAGE","03160"],"gpt_icon":0},{"id":"2620294134","title":"Press Release: Abeona Therapeutics(R) Reports Full Year 2025 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620294134","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620294134?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747000,"startTime":"0","endTime":"0","summary":"- First ZEVASKYN commercial patient treatment completed in December -. - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 -. CLEVELAND, March 17, 2026  -- Abeona Therapeutics Inc.  today reported financial results for the full year of 2025 and recent operational progress.\"2026 is about building a steady cadence of biopsies and treatments,\" said Vish Seshadri, Chief Executive Officer of Abeona. \"We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us to scale-up ZEVASKYN in 2026 and beyond.\". release assay in 2025, ZEVASKYN commercial launch activities commenced in. the fourth quarter, with the first patient treatment completed in. Since resuming manufacturing in late January 2026, multiple biopsies have. has completed treatment with ZEVASKYN so far in 2026, and other collected. Abeona reported total revenue of $5.8 million for the year e","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","BK4232","TM","BK4585","BK4604","R","BK4588","BK4022","BK4555","03160","BK4099","BK4139"],"gpt_icon":0},{"id":"2620749146","title":"Press Release: AEye Reports Fourth Quarter and Full-Year 2025 Results; Strengthened Foundation for Commercial Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2620749146","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620749146?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:35","pubTimestamp":1773693300,"startTime":"0","endTime":"0","summary":"Revenue Doubled in Q4 over Q3; 40% Commercial Pipeline Expansion; 33% Increase in Customer Count. Joining NVIDIA Halos AI Systems Inspection Lab; Demonstrated Apollo Lidar with NVIDIA DRIVE AGX Thor. AEye, Inc.  , a global leader in software-defined, high-performance lidar solutions, today announced financial results for the fourth quarter and full year ended December 31, 2025.--  NVIDIA Ecosystem Maturity: Joining NVIDIA Halos AI Systems Inspection. Lab to bolster automotive product readiness and demonstrated Apollo. lidar with the NVIDIA DRIVE AGX Thor platform, the future centralized. increase since the Company reported Q3 results in November 2025.multiple new requests for quotations , and a new distribution. resolution greater than twice that of AEye's flagship Apollo sensor,packaged in a smartphone-sized form factor which, like Apollo, can. \"Throughout 2025 we made consistent progress towards industrial scaling and active commercial execution,\" said Matt Fisch, CEO of AEye. \"We ar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["3NVD.UK","NVD3.UK","LU0096362180.USD","LU1119994496.HKD","LU2473716301.USD","LU2097344431.USD","NVD","LU0198837287.USD","NVDS","LU2065170008.USD","LIDR","LU2065171311.SGD","LU0354030511.USD","SGXZ99366536.SGD","03160","ANV","IE00B775H168.HKD","NVDB","SNVD.UK","LU0345769631.USD","LU0823421333.USD","2NVD.UK","NVDU","LU1066051225.USD","LU2602419157.SGD","LU2264538146.SGD","NVII","LU0640476718.USD","LU0719512351.SGD","LU0267386448.USD","DIPS","TM","LU2471134796.USD","NVIW.SI","LU0823434740.USD","NVDG","NVDW","NVDX","NVDQ","SG9999002224.SGD","IE00BQXX3F31.USD","LU2250418816.HKD","NVD2.UK","LU0943347566.SGD","NVDD","NVDY","NVDS.UK","LU0175139822.USD"],"gpt_icon":1},{"id":"2620499642","title":"Press Release: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499642","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499642?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:05","pubTimestamp":1773691500,"startTime":"0","endTime":"0","summary":"Atara delivers significant operational efficiencies and extends cash runway through year-end 2026. A Type A meeting has been scheduled between Pierre Fabre Pharmaceuticals and the FDA. Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus  T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates.A Type A meeting with the U.S. Food and Drug Administration  has been scheduled for our partner Pierre Fabre Pharmaceuticals to discuss the issues raised by the FDA in the Complete Response Letter received in January 2026. We anticipate providing a regulatory update in the second quarter.million for the fourth quarter and fiscal year 2025, as compared to $24.5. and fiscal year 2025, respectively, as compared to a net loss of . million, or  per share, and  million, or  per sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","TM","BK4588","ATRA","R","03160","BK4139","PRGS","BK4099","BK4097","BK4555","BK4585","BK4604","LU2065732104.USD","BK4022"],"gpt_icon":0},{"id":"2620870499","title":"Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620870499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620870499?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer  is actively enrolling and remains on track for. -- Positive results from the investigator-sponsored study of FG-3246 in. combination with enzalutamide in patients with mCRPC, further validating. key Phase 2 monotherapy design elements, were presented at the 2026 ASCO. \"The encouraging results from the investigator-sponsored combination trial of FG-3246 with enzalutamide provide us with valuable insights and reinforce key design elements in our Phase 2 monotherapy study,\" said Thane Wettig, Chief Executive Officer of Kyntra Bio. \"Our Phase 2 monotherapy trial of FG-3246 is progressing as planned, with interim results expected in the second half of 2026. Additionally, we have submitted the Phase 3 trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and expect feedback from the FDA shortly, with the intention to start a Phase 3 trial in the second half of 2026. With","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","R","BK4099","LU0128525689.USD","LU1267930490.SGD","LU0052756011.USD","LU1267930227.SGD","LU0310800965.SGD","BK4080","DD","BK4604","KYNB","BK4588","BK4109","BK4504","BK4022","TM","BK4139","03160","BK4585","BK4231","ADC","BK4555","LU0310799852.SGD","BK4232","LU0211328371.USD","LU0211327993.USD"],"gpt_icon":0},{"id":"2620499862","title":"Press Release: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499862","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499862?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:01","pubTimestamp":1773691260,"startTime":"0","endTime":"0","summary":"NEWARK, N.J., March 16, 2026  -- Rafael Holdings, Inc.  today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026.\"We remain pleased with the progress of our pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee  recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol Cyclo could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,\" said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.\"We are on track to complete this 96-week Phase 3 clinical trial, the largest ever conducted in this indication, and report preliminary top line results in the third quarter of this calendar year,\" said Joshua Fine, Chief Operating Officer of Rafael Holdings.Research and development expenses were $12.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4585","BK4588","03160","BK4604","BK4232","BK4099","BK4022","BK4007","RFL","BK4205","TM","BK4233","BK4555"],"gpt_icon":0},{"id":"2619462553","title":"Opening Day: SoftBank payments app operator makes public debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2619462553","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619462553?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:10","pubTimestamp":1773673850,"startTime":"0","endTime":"0","summary":"SoftBank’s payments app operator made its public debut last week, with PayPay beginning trade above its $16 IPO price. LATEST IPOS AND DIRECT LISTI...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-softbank-payments-app-operator-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-softbank-payments-app-operator-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4132","03160","SFTBY","PAYP"],"gpt_icon":0},{"id":"2619450024","title":"Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 16, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC  and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC .Under the amendment to the Existing Note, the maturity date of the Existing Note has been extended to December 31, 2026, with no other changes to the terms. The lender has confirmed that the Existing Note is not in default.In addition, Outlook Therapeutics entered into the $18.4 million New Note. The Company expects to receive $17 million in net proceeds, after original issue discount. Proceeds from the New Note will be used to pay down a portion of the Existing Note, reducing the balance and leaving approximately $10.8 million of principal and interest remaining on the Existing Note.The New Note bears interest at a rate equal to th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMUU","LU0082616367.USD","AMDD","LU0889565833.HKD","BK4141","LU1951200564.SGD","LU0056508442.USD","LU1988902786.USD","LU2931357623.SGD","LU1923623000.USD","AMDL","AMYY","BK4588","LENZ","BK4566","03160","AMDU","DAMD","LU1242518931.SGD","OTLK","LU0390134368.USD","BK4539","BK4554","LU1989764664.SGD","IE00BMPRXN33.USD","AMDY","LU2458330169.SGD","BK4573","LU2098885051.SGD","LU1951198990.SGD","LU0719512351.SGD","LU0109392836.USD","AMDW","LU0823421333.USD","BK4543","BK4007","TM","LU1880398554.USD","LU1316542783.SGD","LU2355687059.USD","BK4612","BK4534","AMDG","LU1880398471.USD","BK4512","BK4604","LU2458330243.SGD","BK4529","LU1064131342.USD"],"gpt_icon":1},{"id":"2619718459","title":"Press Release: Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2619718459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619718459?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:03","pubTimestamp":1773655380,"startTime":"0","endTime":"0","summary":"-- Acquisition of ALTO-207 targets Treatment-Resistant Depression  with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 --. -- External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments --. -- ALTO-101 granted FDA Fast Track Designation for CIAS; Topline Phase 2 Proof-of Concept data expected around the end of 1Q 2026 --. --  Acquisition and Accelerated Development of ALTO-207 for TRD: In June. patent coverage of ALTO-207 through at least the mid 204","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","ANRO","BK4007","BK4604","PIPE","BK4588","BK4585","CIAS","03160","BK4099","TM"],"gpt_icon":0},{"id":"2619434441","title":"Press Release: BALYO Announces Its 2025 Results, Marked by a Further Increase in Revenue (+8%) to EUR31.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619434441","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619434441?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:45","pubTimestamp":1773643500,"startTime":"0","endTime":"0","summary":"--  Annual sales of EUR31.4 million, up +8% vs. 2024. --  Backlog1 to EUR21.9 million as of December 31, 2025. --  Update regarding the shareholder loan agreement with SoftBank. BALYO , technology leader in the design and development of innovative robotic solutions for industrial trucks, today announces its full-year 2025 results, as approved by the Board of Directors on March 11, 2026.Pascal Rialland, CEO of BALYO, states: \"The 2025 financial year confirmed BALYO's growth momentum, with annual revenue up 8% to EUR31.4 million, despite a slight decline in the fourth quarter. It has been driven in particular by strong growth in the United States, which rose 41% in 2025. This performance was nevertheless below Company's expectations. This growth was accompanied by a stable gross margin of 31%. At the same time, in line with BALYO's DNA, we continued our strategic investments, particularly in R&D and Sales & Marketing, in order to support our growth trajectory and strengthen our technolog","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: BALYO Announces Its 2025 Results, Marked by a Further Increase in Revenue (+8%) to EUR31.4 Million","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","SFTBY","03160"],"gpt_icon":0},{"id":"2619112669","title":"Toyota Hit By Major US Recall Of 550,000 SUVs","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112669","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112669?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:05","pubTimestamp":1773425100,"startTime":"0","endTime":"0","summary":"Toyota recalls 550k SUVs in the U.S. and slashes Middle East production as Iran-U.S. tensions disrupt exports. Get the TM stock impact.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/13/Mexico-City--Mexico-Marc-2-2024--Toyota-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/13/Mexico-City--Mexico-Marc-2-2024--Toyota-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/03/51249792/toyota-hit-by-major-us-recall-of-550000-suvs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/03/51249792/toyota-hit-by-major-us-recall-of-550000-suvs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4099","03160","TM","BK4585","BK4555","BK4604","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}